Olanzapine
- Generic Name
- Olanzapine
- Brand Names
- Lybalvi, Olazax, Symbyax, Zalasta, Zypadhera, Zyprexa, Olanzapine Glenmark Europe, Olanzapine Apotex, Olanzapine Teva, Olazax Disperzi, Olanzapine Mylan, Zyprexa Velotab, Olanzapine Glenmark
- Drug Type
- Small Molecule
- Chemical Formula
- C17H20N4S
- CAS Number
- 132539-06-1
- Unique Ingredient Identifier
- N7U69T4SZR
- Background
Olanzapine is a thienobenzodiazepine classified as an atypical or second-generation antipsychotic agent. The second-generation antipsychotics were introduced in the 90s and quickly gained traction due to their impressive efficacy, reduced risk for extrapyramidal side effects and reduced susceptibility to drug-drug interactions. Olanzapine very closely resemb...
- Indication
Olanzapine was initially used orally and intramuscularly for the chronic treatment of schizophrenia in patients over 13 years old and other psychiatric disorders such as bipolar I disorder including mixed or manic episodes.
...
- Associated Conditions
- Acute Agitation, Bipolar 1 Disorder, Bipolar Disorder With Manic or Mixed Episodes, Delirium, Delusional Parasitosis, Depressive Episodes, Gilles de la Tourette's Syndrome, Major depressive disorder, recurrent episode, Mixed manic depressive episode, Post Traumatic Stress Disorder (PTSD), Psychosis, Schizophrenia, Acute Manic episode
- Associated Therapies
- -
Study to Evaluate Weight Gain As Assessed by Change in BMI Z-score in Pediatric Subjects with Schizophrenia or Bipolar I Disorder
- Conditions
- Interventions
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 220
- Registration Number
- NCT05303064
- Locations
- 🇺🇸
Alkermes Investigational Site, Kinston, North Carolina, United States
🇲🇽Alkermes Investigator Site, Monterrey, Mexico
The Optimization of Antiemetic Regimen for C-RINV in LA-HNSCCs
- Conditions
- Interventions
- First Posted Date
- 2022-01-21
- Last Posted Date
- 2022-01-21
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 43
- Registration Number
- NCT05202275
- Locations
- 🇨🇳
Ye Zhang, Beijing, Beijing, China
Olanzapine in OUD Patients
- First Posted Date
- 2022-01-05
- Last Posted Date
- 2023-02-01
- Lead Sponsor
- University of Pennsylvania
- Registration Number
- NCT05179772
- Locations
- 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸Virginia Commonwealth University, Richmond, Virginia, United States
Comparing Olanzapine and Mirtazapine in the Improvement of Unintentional Weight Loss for Patients With Advanced Stage Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-12-28
- Last Posted Date
- 2022-07-26
- Lead Sponsor
- Englewood Hospital and Medical Center
- Target Recruit Count
- 170
- Registration Number
- NCT05170919
- Locations
- 🇺🇸
Englewood Health, Englewood, New Jersey, United States
Olanzapine Versus Megestrol Acetate for the Treatment of Loss of Appetite Among Advanced Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2021-06-25
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 360
- Registration Number
- NCT04939090
- Locations
- 🇺🇸
Missouri Baptist Sullivan Hospital, Sullivan, Missouri, United States
🇺🇸BJC Outpatient Center at Sunset Hills, Sunset Hills, Missouri, United States
🇺🇸Billings Clinic Cancer Center, Billings, Montana, United States
Efficacy of Olanzapine, Netupitant and Palonosetron in Controlling Nausea and Vomiting Associated With Highly Emetogenic Chemotherapy in Patients With Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-12-16
- Last Posted Date
- 2022-02-23
- Lead Sponsor
- Instituto Brasileiro de Controle do Cancer
- Target Recruit Count
- 50
- Registration Number
- NCT04669132
- Locations
- 🇧🇷
IBCC Oncologia, São Paulo, Brazil
Clinical Intervention on Cognitive Impairment of Schizophrenia With Metabolic Syndrome
- Conditions
- Interventions
- First Posted Date
- 2020-08-19
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- Shanghai Mental Health Center
- Target Recruit Count
- 120
- Registration Number
- NCT04518319
- Locations
- 🇨🇳
Shanghai Mental Health Center, Shanghai, Shanghai, China
Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting in Gynecologic Oncology Patients
- Conditions
- Interventions
- First Posted Date
- 2020-08-07
- Last Posted Date
- 2024-06-10
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 62
- Registration Number
- NCT04503668
- Locations
- 🇺🇸
University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States
"Extended" (Alternate Day) Antipsychotic Dosing
- Conditions
- Interventions
- First Posted Date
- 2020-07-21
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- Centre for Addiction and Mental Health
- Target Recruit Count
- 120
- Registration Number
- NCT04478838
- Locations
- 🇨🇦
Centre for Addiction and Mental Health, Toronto, Ontario, Canada
Amisulpride Treatment for BPSD in AD Patients
- Conditions
- Interventions
- First Posted Date
- 2020-04-10
- Last Posted Date
- 2022-11-16
- Lead Sponsor
- Tianjin Anding Hospital
- Target Recruit Count
- 76
- Registration Number
- NCT04341467
- Locations
- 🇨🇳
Tianjin Anding Hospital, Tianjin, Tianjin, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.